Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.
🟢 New in Current Filing
•Our use of artificial intelligence (AI) or other emerging technologies could adversely impact our business and financial results.
🔒
🔴 No Match in Current Filing
•Public health outbreaks, epidemics, or pandemics, such as the COVID-19 pandemic, have adversely impacted and may in the future adversely impact our business and operations.
🔒
🟡 Modified
•Failure, inadequacy, breach of, or unauthorized access to, our IT systems or those of our third-party service providers, unauthorized access to our confidential information, or violations of data protection laws, could each result in material harm to our business and reputation.
🔒
🟡 Modified
•We are subject to evolving and complex tax laws, which may result in additional liabilities and affect our results of operations.
🔒
🟡 Modified
•Pharmaceutical research and development is very costly and highly uncertain; we may not succeed in developing, licensing, or acquiring commercially successful products sufficient in number or value to replace revenues of products that have lost or will lose intellectual property protection or are displaced by competing products or therapies.
🔒
🟡 Modified
•We and our products face intense competition from multinational pharmaceutical companies, biotechnology companies, and lower-cost generic and biosimilar manufacturers, and such competition could have a material adverse effect on our business.
🔒
🟡 Modified
•Manufacturing, quality, or supply chain difficulties, disruptions, or shortages could lead to product supply problems.
🔒
🟡 Modified
•Our long-term success depends on intellectual property protection; if our intellectual property rights are invalidated, circumvented, or weakened, our business will be adversely affected.
🔒
🟡 Modified
•Regulatory compliance problems could be damaging to the company.
🔒
🟡 Modified
•Reliance on third-party relationships and outsourcing arrangements could adversely affect our business.
🔒
🟡 Modified
•We depend on products with intellectual property protection for most of our revenues, cash flows, and earnings; the loss of effective intellectual property protection for certain of our products has resulted, and in the future is likely to continue to result, in rapid and severe declines in revenues for those products.
🔒
🟡 Modified
•Pharmaceutical products can develop safety or efficacy concerns, which could have a material adverse effect on our revenues, income, and reputation.
🔒
🟡 Modified
•We face litigation and investigations related to our products, how we price or commercialize our products, and other aspects of our business, which could adversely affect our business, and we are self-insured for such matters.
🔒
🟡 Modified
•We derive a significant percentage of our total revenue from relatively few products and sell our products through increasingly consolidated supply chain entities, which may subject us to, or exacerbate, various risks.
🔒
🟡 Modified
•Our business is subject to increasing government price controls and other public and private restrictions on pricing, reimbursement, and access for our drugs, which could have a material adverse effect on our results of operations, reputation or business.
🔒
🟡 Modified
•Uneven economic growth or downturns or international trade and other global disruptions, geopolitical tensions, or disputes could adversely affect our business and operating results.
🔒